Mykhaylo Mudryk Joins Tottenham on Loan After Doping Ban: Transfermarkt Values Ukrainian at €15m

Mykhaylo Mudryk officially joined Tottenham Hotspur on a season-long loan from Chelsea on 1 September 2026, ending a near two-year competitive absence caused by a meldonium doping case that resulted in an initially imposed four-year ban later resolved to time served. Transfermarkt assigned the 25-year-old Ukrainian winger a market value of €15 million on 4 September 2026 — his first valuation in over a year and €3 million below his pre-suspension figure — reflecting the uncertainty that still surrounds the player’s return to form at the highest level.

The Football Association confirmed that Mudryk is “no longer ineligible and may return to competition with immediate effect” in late July 2026, after agreeing with the World Anti-Doping Agency (WADA) that, under current anti-doping procedures, the meldonium concentration found in his sample would not have been reportable. Mudryk accepted the violation and the period of ineligibility equal to time already served, effectively clearing the path for his return to professional football after the Ukrainian had last played a competitive match in November 2024.

Sky Sports reported that the Tottenham deal includes an option to buy the winger, giving Ange Postecoglou’s side a route to a permanent acquisition if Mudryk re-establishes himself in the Premier League following one of the most turbulent doping cases in English football’s recent history.

The Doping Case: Meldonium, a Four-Year Ban, and a Long Road Back

Mudryk’s world came crashing down in late 2024 when an adverse analytical finding was confirmed by the FA. The banned substance was meldonium — a heart medication used for cardiovascular conditions that is also known to enhance endurance and oxygen utilisation, and which has been banned by WADA since 2016. The FA initially imposed a four-year suspension, a ruling that appeared to end what had been a promising, if inconsistent, career at the highest level for the Ukrainian winger.

Mudryk immediately launched an appeal at the Court of Arbitration for Sport (CAS), with his legal team arguing the context and circumstances of the positive test. The appeal process stretched through 2025 and into 2026, with Mudryk unable to play competitive football throughout that period. According to The Athletic’s detailed explainer published on 2 September 2026, the resolution came through an agreement between the FA and WADA acknowledging that under current anti-doping procedures the meldonium concentration in his sample “would not have been reported” — a significant procedural acknowledgment that mitigated the severity of the original ruling.

The FA’s official statement confirmed: “Mr Mudryk is no longer ineligible and may return to competition with immediate effect.” The statement further clarified that the updated anti-doping procedures had changed the threshold at which such a meldonium concentration would be flagged, and that Mudryk had accepted the violation alongside the period of ineligibility that equated to time already served. This outcome, announced in late July 2026, allowed Chelsea to immediately start planning what would happen to the player for the 2026-27 season.

From Chelsea’s Record Signing to Tottenham’s Loan Bet

Mudryk’s journey from Shakhtar Donetsk to England had been one of the most dramatic in recent Premier League history even before the doping case. Chelsea signed the Ukrainian winger in January 2023, outbidding Arsenal in a headline-grabbing transfer that reportedly cost the London club in the region of £88.5 million. The move was seen as a statement of Chelsea’s ambition under their new American ownership group, and Mudryk — widely compared to Kylian Mbappé in terms of raw pace and directness — arrived at Stamford Bridge with enormous expectations attached.

The reality at Chelsea proved more complicated. Mudryk showed flashes of his undeniable talent — the explosive acceleration, the direct dribbling, the ability to beat defenders with sheer pace — but consistent performances in the Premier League eluded him. Questions over decision-making in the final third and consistency in defensive tracking dogged his time at the club, and by the time the doping suspension hit in late 2024, Mudryk had failed to fully justify that nine-figure price tag. He had not played a competitive game since November 2024 when the loan to Tottenham was confirmed on deadline day, 1 September 2026.

For Chelsea, the loan offered a pragmatic solution: generate some value from a player whose wages continued to be a significant burden during the ban, while Mudryk rebuilt his match sharpness and public standing elsewhere. Sky Sports confirmed the loan deal on 1 September 2026, with an option to buy giving Tottenham the right to make the move permanent, subject to Mudryk’s performances throughout the campaign.

Transfermarkt’s €15m Verdict: What the Market Thinks of Mudryk Now

On 4 September 2026, Transfermarkt published Mudryk’s first market value update in over a year, setting it at €15 million. The figure is €3 million lower than the valuation he held before the doping suspension took effect, and it underscores the degree of uncertainty that now surrounds one of football’s most expensive — and most controversial — recent investments.

According to Transfermarkt’s analysis published on 4 September 2026, the €15 million valuation reflects both the inherent risk of a player returning from nearly two years out of competitive action and the option-to-buy clause in his Tottenham loan, which Transfermarkt noted was reported to be set significantly higher — at around €72 million according to the German-language edition of the platform. The gulf between the current market value and the purchase option price illustrates the extreme nature of this gamble: Tottenham have an opportunity to lock in a player at a price that would represent extraordinary value if Mudryk returns to even a fraction of his pre-ban form, but the inherent risk is enormous given how long he has been out.

For context, the €15 million figure places Mudryk far below the valuation levels of comparable Premier League wide forwards. It is a sobering reminder of how swiftly market value can collapse in the wake of a doping case and a near two-year absence — regardless of a player’s underlying talent.

What Mudryk Offers Tottenham — and What They’re Risking

At his best, Mykhaylo Mudryk is a nightmare for Premier League defenders. His defining qualities are exceptional — raw pace that puts him among the fastest players in Europe, the ability to carry the ball at high speed through congested defensive lines, and an unpredictability in one-on-one situations that few wide players at any level can match. Born on 5 January 2001 in Krasnohrad, Ukraine, Mudryk emerged from the Shakhtar Donetsk academy system and rapidly established himself as one of the most exciting attackers in European football before the move to England, drawing comparisons with some of the continent’s elite forwards.

Tottenham’s decision to take the gamble is understandable from a squad-building and financial perspective. A loan with an option to buy means they take on limited financial risk while acquiring a player with genuinely elite physical attributes. If the Premier League minutes and match rhythm help Mudryk rediscover his form and sharpen the decision-making that was always the weaker part of his game, Tottenham have landed one of the most exciting potential bargains in the division. The risk, of course, is that nearly two years without competitive football has dulled those attributes in ways that only time on the pitch will reveal.

For the Ukrainian national team context, the Tottenham move is also significant. Mudryk remains a key figure in Ukraine’s football ambitions, and his return to competitive football at a top-six Premier League club strengthens the nation’s pool of active, high-level players for international fixtures. His absence had been felt both domestically and in the broader European football conversation.

The Broader Context: Meldonium in Football and WADA’s Evolving Standards

The meldonium substance at the centre of Mudryk’s case has a complicated history in sport. It was added to WADA’s prohibited list on 1 January 2016, and in the years immediately after the ban hundreds of athletes across multiple sports — predominantly from Eastern European countries — returned positive tests. The substance, developed in Latvia and marketed under the brand name Mildronate, had long been prescribed for cardiovascular conditions and was widely used in Eastern European sports medicine, often without athletes being fully aware it had been prohibited.

The key nuance in Mudryk’s case — and the basis on which the FA and WADA agreed to resolve it — is the evolution of detection thresholds. WADA subsequently updated its guidelines on how to interpret meldonium concentrations in samples, recognising that trace amounts could persist in the body for extended periods after legitimate historical use. The FA’s acknowledgment that the concentration in Mudryk’s sample “would not have been reported” under current procedures is a significant concession that contextualises the resolution without fully exonerating the player of an initial violation.

It is a legally complex outcome that satisfies neither those who believe any banned substance finding should carry the full original penalty, nor those who argue Mudryk was a victim of outdated detection procedures. The resolution nonetheless carries the authority of an agreement between the FA, WADA, and the player — the principal bodies in any such case — and stands as the definitive legal outcome of an extraordinary episode.

Chelsea’s Perspective: Managing a £88.5m Asset Through Crisis

From Chelsea’s perspective, the saga has been one of the costliest and most frustrating in a period already defined by enormous and often controversial expenditure. The January 2023 acquisition represented one of the largest fees paid for a wide forward in Premier League history, and the subsequent disruption caused by the doping suspension left the club with a major financial commitment and no return on the pitch for the best part of two years.

The loan to Tottenham — a direct London rival — carries its own narrative tension. Sending Mudryk to Spurs is a pragmatic commercial decision, but it is one that underscores Chelsea’s willingness to prioritise financial common sense over the rivalry optics. If Mudryk flourishes at Tottenham and they exercise the option to buy, Chelsea will recoup a fee that, given the circumstances, might be considered a reasonable outcome. If the loan fails and Mudryk returns to Stamford Bridge, Chelsea face the unenviable prospect of reintegrating a player whose form and value remain deeply uncertain.

The situation echoes, in some respects, other high-profile cases where Premier League clubs have had to manage significant long-term financial commitments to players whose careers were disrupted by injury, form, or off-field issues. The difference here is the scale of the original investment and the unprecedented nature of the doping circumstances.

Timeline: Mudryk’s Doping Case and Return to Football

• January 2023: Chelsea sign Mudryk from Shakhtar Donetsk in a deal reportedly worth up to £88.5 million.
• November 2024: Mudryk plays his last competitive match before the positive test is confirmed.
• Late 2024: FA confirms adverse analytical finding; meldonium identified as the prohibited substance.
• 2024-2025: FA imposes four-year ban. Mudryk lodges appeal at the Court of Arbitration for Sport (CAS).
• April 2026: Appeal proceedings continue; The Athletic details the legal complexity of the CAS process.
• Late July 2026: FA and WADA reach agreement; ban resolved to time served; Mudryk cleared to return immediately.
• 1 September 2026: Mudryk joins Tottenham Hotspur on season-long loan from Chelsea; option to buy included.
• 2 September 2026: The Athletic publishes comprehensive explainer on the doping case and what happens next.
• 4 September 2026: Transfermarkt assigns Mudryk a market value of €15 million — his first valuation in over a year.

What Happens Next: Mudryk’s Return and the Option-to-Buy Question

The immediate football question is straightforward: can Mudryk regain his form quickly enough to justify Tottenham’s faith — and ultimately Chelsea’s purchase option clause? The physical attributes that made him one of Europe’s most coveted young wingers before the ban are unlikely to have disappeared entirely, but match fitness, timing, and the sharpness that comes only from competitive football are qualities that cannot be shortcut after a near two-year absence.

Tottenham’s coaching staff will be acutely aware of the need to manage Mudryk’s return carefully — building match minutes gradually rather than throwing him immediately into the deep end of Premier League intensity. The Athletic’s coverage on 4 September 2026, contextualising Mudryk’s situation ahead of Tottenham’s early-season fixtures, suggests the club are approaching his reintegration methodically.

The purchase option, reportedly in the region of €72 million according to Transfermarkt’s German-language analysis, would represent a substantial investment for Tottenham — but one that would make sense only if Mudryk performs consistently at his pre-ban level. Given his current €15 million market value, the gap between the two figures captures perfectly the extraordinary binary nature of this gamble: an enormous upside if it works, a manageable loss if it doesn’t.

For Chelsea, the 2026-27 season will be a watching brief. They retain contractual control of a player in whom they have invested an enormous sum, and the outcome of the Tottenham loan will define what options they have going forward — whether that is a permanent sale, a further loan, or an eventual reintegration at Stamford Bridge. What is certain is that the Mudryk saga, for all its twists, is far from over. Football’s most extraordinary doping redemption story is only just beginning its latest chapter.

Supporters interested in Chelsea’s broader transfer strategy this summer can find additional context in our analysis of Premier League free-agent moves and in our coverage of off-field controversies affecting Premier League players this season.

Sources

• The Athletic’s detailed explainer published on 2 September 2026 — nytimes.com
• Mykhailo Mudryk transfer news: Tottenham sign Chelsea winger on … — skysports.com
• Transfermarkt’s analysis published on 4 September 2026 — transfermarkt.us
• Mudryk joins Spurs on loan from Chelsea after doping ban ends — sports.yahoo.com
• Mudryk leaves Chelsea for Tottenham on loan in bid to reignite career after doping case — sports.yahoo.com